Coach Mpilo peer support for men with TB and HIV

Assessing the Feasibility of Coach Mpilo for Men With TB and HIV in Eastern Cape, South Africa

Not applicable Interventional Arizona State University · NCT07117370

We will test whether Coach Mpilo, a peer-support program developed by men, helps men starting TB treatment — including those with HIV — complete TB therapy and achieve better HIV viral suppression.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment240 (estimated)
Ages18 Years and up
SexMale
SponsorArizona State University Academic / other
Locations1 site (East London)
Trial IDNCT07117370 on ClinicalTrials.gov

What this trial studies

This project will adapt the Coach Mpilo peer-support model for men initiating TB treatment and for men with TB/HIV co-infection, creating CM-TB and CM-TB/HIV versions. Using the ADAPT-IIT model and a mixed-methods approach, investigators will conduct interviews, role simulations, and a small pre-test/pilot to refine the intervention. Subsequent implementation will enroll men initiating or re-initiating TB therapy in Buffalo City Metro (BCM) Health Districts to measure feasibility and collect secondary outcomes on TB treatment completion and HIV viral suppression. Findings will inform a later Hybrid Type I implementation-effectiveness effort.

Who should consider this trial

Good fit: Men aged 18 or older who live in BCM Health Districts and are newly starting or re-starting TB treatment, and for the HIV-focused arm those who are HIV-positive and not yet on ART, are the ideal candidates.

Not a fit: Women, people under 18, those living outside the BCM districts, and people who are not initiating or re-initiating TB treatment (or who are already on ART for the HIV arm) are not eligible and are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, this peer-support approach could increase TB treatment completion and improve HIV viral suppression among men, reducing morbidity and onward transmission.

How similar studies have performed: Coach Mpilo has been used as a peer-support HIV treatment intervention for men in South Africa with prior positive signals for improving HIV outcomes, but its adaptation specifically for TB/HIV is novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

Aim 2: 1) men; 2) aged ≥18 years; 3) newly initiating (i.e., treatment naive) or re-initiating TBT after being loss-from-care per South African national guidelines; 4) live in BCM Health Districts; and 5) provide written informed consent.

Aim 3: 1) men; 2) aged ≥18 years; 3) newly initiating (i.e., treatment naive) or re-initiating TBT after being loss-from-care per South African national guidelines; 4) HIV-positive; 5) Not on ART, 6) live in BCM Health Districts; and 7) provide written informed consent.

Exclusion Criteria:

Aim 2: 1) Not a man; 2) aged \< 18 years; 3) not initiating (i.e., treatment naive) or not re-initiating TBT after being loss-from-care per South African national guidelines; 4) not live in BCM Health Districts; and 5) cannot provide written informed consent.

Aim 3: 1) Not a man; 2) aged \< 18 years; 3) not initiating (i.e., treatment naive) or not re-initiating TBT after being loss-from-care per South African national guidelines; 4) not HIV-positive; 5) on ART, 6) not live in BCM Health Districts; and 7) cannot provide written informed consent.

Where this trial is running

East London

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions TuberculosisHIV
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.